News Sentiment

BMY sentiment intelligence

Bristol-Myers Squibb Company news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors Options RSS feed
Weighted score 51 Balanced news tone 35 relevant articles
Exchange NYSE United States
Sector Healthcare Market context
Industry Drug Manufacturers - General Read-through group
Latest close 65.31 Week of 31 Jul 2026
Weighted tone 51/100

Balanced news tone

Market reaction Price moving ahead of tone

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy

76/100 classification confidence.

Company focus 35

directly relevant articles

Source quality 8

high-authority source matches

Trend context Trend active

+5.2% over one week, +12.4% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

PensionDanmark Pensionsforsikringsaktieselskab Buys 38,596 Shares of Bristol Myers Squibb Company $BMY

Market Reaction

Price moving ahead of tone

58/100 confidence

Price is moving more forcefully than the current news tone suggests.

Primary event Deals and strategy 76/100 classification
One-week reaction 5.2% Price confirming higher
Trend fit Trend active 12.4% over four weeks
Fair value 32.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 8
Neutral 23
Negative 4

Relevance

Why the article matched

Direct first
Direct company coverage 35
Industry context 0
Sector context 0

Sources

Coverage mix

Publishers
finance.yahoo.com 6
simplywall.st 4
MarketBeat 2
Reuters 2
WSJ 2
Pharmaceutical Executive 2
Market source 2
Yahoo! Finance Canada 1

Event Lens

What the news is about

Classified themes
Deals and strategy 15
Market update 14
Earnings 4
Regulatory and legal 1
Capital return 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 35
Reuters Direct company coverage

US FDA approves Replimune's skin cancer drug after prior rejections

The U.S. FDA has approved Replimune's drug Tudriqev, in combination with Bristol Myers Squibb's Opdivo, for a difficult-to-treat form of advanced melanoma. This approval marks Replimune's first marketed product after previous rejections, and the drug will compete with Iovance Bio

Tone
Positive 67/100
Event
Regulatory and legal
Published
06 Aug 2026 20:26
Source
Reuters
WSJ Direct company coverage

Deal or No Deal, AstraZeneca Stock Is a Bargain

AstraZeneca's stock has become a potential bargain after recent investor concerns over a rumored megamerger with Bristol-Myers Squibb. Despite CEO Pascal Soriot's reputation for fostering growth through internal R&D and smaller, targeted acquisitions, the company's shares are dow

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Aug 2026 09:39
Source
WSJ
Pharmaceutical Executive Direct company coverage

Beyond the Megamerger: How Rumored AstraZeneca–BMS Discussions Signal a New Era of Pharmaceutical Competition

Rumors of a potential AstraZeneca-Bristol Myers Squibb merger, despite being disputed, highlight a fundamental shift in pharmaceutical competition. The article suggests that future success in the industry will depend not just on scientific innovation, but on integrated capabiliti

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Aug 2026 07:07
Source
Pharmaceutical Executive
Yahoo! Finance Canada Direct company coverage

Schrödinger (SDGR) Is Up 8.5% After AI Co‑Scientist Deal With BMS And Q2 Profitability Shift – Has The Bull Case Changed?

Schrödinger, Inc. reported strong Q2 2026 results with a shift to profitability and a significant expansion of its AI co-scientist collaboration with Bristol Myers Squibb. This deal, involving the new agentic AI Bunsen, reinforces the company's AI-driven growth ambitions and its

Tone
Positive 65/100
Event
Earnings
Published
06 Aug 2026 06:12
Source
Yahoo! Finance Canada
pharmaphorum Direct company coverage

Sources quash rumours of an AZ/BMS mega-merger

Reports from Reuters indicate there is no truth to the rumors of a potential $400 billion mega-merger between AstraZeneca (AZ) and Bristol Myers Squibb (BMS). A senior source close to the matter confirmed that no such deal was ever contemplated, nor are there ongoing discussions

Tone
Positive 67/100
Event
Deals and strategy
Published
06 Aug 2026 05:37
Source
pharmaphorum
PYMNTS.com Direct company coverage

CPI | AstraZeneca, Bristol Myers Dismiss Merger Talk Speculation

AstraZeneca Plc and Bristol Myers Squibb Co. have dismissed speculation regarding a potential merger, stating they are not engaged in such discussions. This clarification came after an earlier report by the Financial Times suggested talks were underway for a $400 billion deal, wh

Tone
Neutral 50/100
Event
Deals and strategy
Published
06 Aug 2026 03:07
Source
PYMNTS.com
Pharmaceutical Executive Direct company coverage

Senior Source Denies AstraZeneca and Bristol Myers Deal Talks : Report

A senior source has denied any ongoing or historical discussions between AstraZeneca and Bristol Myers Squibb regarding a potential merger, contradicting earlier speculation about a nearly $400 billion deal. The denial follows initial reports that caused AstraZeneca's shares to d

Tone
Negative 42/100
Event
Deals and strategy
Published
05 Aug 2026 15:07
Source
Pharmaceutical Executive
BioSpace Direct company coverage

No deal between AstraZeneca and BMS, senior source insists: Reuters

Reuters has reported that rumors of a merger between AstraZeneca and Bristol Myers Squibb are false, according to a senior source close to the matter. This news deflates widespread speculation about what could have been the largest pharmaceutical deal in history, valued at approx

Tone
Negative 38/100
Event
Deals and strategy
Published
05 Aug 2026 15:07
Source
BioSpace
Quartz Direct company coverage

Senior source denied AstraZeneca and Bristol Myers Squibb were ever in merger talks

A senior source close to the matter denied that AstraZeneca and Bristol Myers Squibb were ever in merger talks, contradicting earlier reports of a potential $400 billion combination. This denial comes after AstraZeneca's shares dropped following the initial reports, while Bristol

Tone
Positive 60/100
Event
Deals and strategy
Published
05 Aug 2026 13:07
Source
Quartz
Reuters Direct company coverage

'No discussions' over AstraZeneca-Bristol Myers deal, senior source says

A senior source close to the matter has stated that there are "no discussions" ongoing between AstraZeneca and Bristol Myers Squibb regarding a potential merger, dispelling recent reports of a mega deal. AstraZeneca's shares initially slid after the Financial Times reported on po

Tone
Negative 34/100
Event
Deals and strategy
Published
05 Aug 2026 12:05
Source
Reuters
Market source Direct company coverage

Schrödinger Announces Strategic Collaboration and Software Agreement with Bristol Myers Squibb to Deploy AI Co-Scientist Bunsen for Agentic Drug Discovery

Schrödinger, Inc. announced a strategic agreement with Bristol Myers Squibb (BMS) to integrate Bunsen, Schrödinger's agentic AI co-scientist, into BMS's research operations. This collaboration expands BMS's use of Schrödinger's computational platform, enabling enhanced exploratio

Tone
Positive 71/100
Event
Market update
Published
05 Aug 2026 08:30
Source
Market source